De testimonio: on the evidence for decisions about the use of therapeutic interventions

The Lancet

Volumn 372, Issue 9656, 2008, Pages 2152-2161

  Rawlins, Michael ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; BAYES THEOREM; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; HEALTH CARE PLANNING; HISTORY OF MEDICINE; INTERNAL VALIDITY; INTERVENTION STUDY; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MEDICAL INFORMATION; MEDICAL RESEARCH; MORTALITY; OBSERVATIONAL STUDY; PATIENT CARE; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

EID: 57649198083     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61930-3     Document Type: Note

References (71)

1. Shapin S. The scientific revolution (1996), University of Chicago Press, Chicago and London
2. Gower B. Scientific method: an historical and philosophical introduction (1997), Routledge, London and New York
3. Harbour R., and Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 323 (2001) 334-336
4. Jadad A.R., and Enkin M.W. Randomized controlled trials. 2nd edn. (2007), BMJ Books, London
5. Rawlins M.D., and Culyer A.J. National Institute for Clinical Excellence and its value judgments. BMJ 329 (2004) 224-227
6. Pocock S.J. Clinical Trials (1983), John Wiley & Sons, Chichester
7. Altman D.G., Schulz K.F., Egger M., et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134 (2001) 663-694
8. Moher D., Schulz K.F., and Altman D.G. The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134 (2001) 657-662
9. Clarke M., Hopewell S., and Chalmers I. Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report. J R Soc Med 100 (2007) 187-190
10. Rawlins M.D. De testimonio (2008), Royal College of Physicians, London
11. Rothman K. No adjustments are needed for multiple comparisons. Epidemiology 1 (1990) 43-46
12. Schulz K.F., and Grimes D.A. Multiplicity in randomised trials II: subgroups and interim analyses. Lancet 365 (2005) 1657-1661
13. Montori V.M., Devereaux P.J., Adhikari N.K.J., et al. Randomised trials stopped early for benefit: a systematic review. JAMA 294 (2005) 2203-2209
14. Armitage P., Berry G., and Matthews J.N.S. Statistical methods in medical research. 4th edn. (2002), Blackwell, Oxford
15. Pocock S.J. When not to stop clinical trials for benefit. JAMA 294 (2005) 2228-2230
16. Pocock S.J., and Lubsen J. More on subgroup analyses. N Engl J Med 358 (2008) 2076
17. Wang R., Lagakos S.W., Ware J., Hunter D.J., and Drazen J.M. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 357 (2007) 2189-2194
18. Ashby D. Bayesian statistics in medicine: a 25 year review. Stat Med 25 (2006) 3589-3631
19. Spiegelhalter D.J., Freedman L.S., and Parmar M.K.B. Bayesian approaches to randomised trials. J R Soc Stat [Ser A] 157 (1994) 357-416
20. Spiegelhalter D.J., Myles J.P., Jones D.R., and Abrams K.R. Bayesian methods in health technology assessment: a review. Health Technol Assess 4 (2000) 38
21. GREAT Group. Feasability, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. BMJ 305 (1992) 548-553
22. Pocock S.J., and Speigelhalter D.J. Grampian region early anastroplase trial. BMJ 305 (1992) 1015
23. Bland J.M., and Altman D.G. Bayesians and frequentists. BMJ 317 (1998) 1151
24. Berry D., Goodman S.N., Louis T.A., and Temple R. Introduction to bayesian methods: floor discussion. Clin Trials 2 (2005) 301-304
25. Food and Drug Administration. Guidance for the use of bayesian statistics in medical device trials (2006), US Department of Health and Human Services, Food and Drug Administration, Centre for Devices and Radiological Health, Bethesda
26. Berry D.A. Introduction to bayesian methods III: use and interpretation of bayesian tools in design and analysis. Clin Trials 2 (2005) 295-300
27. Grieve A.P. 25 years of Bayesian methods in the pharmaceutical industry: a personal, statistical bummel. Pharm Stat 6 (2007) 261-361
28. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 312 (1996) 1215-1218
29. Rothwell P.M. External validity of randomised controlled trials: "To whom do the benefits apply?". Lancet 365 (2005) 82-93
30. Bartlett C., Doyal L., Ebrahim S., Davey P., et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess 9 (2005) 38
31. Heiat A., Gross C.P., and Krumhplz H.M. Representation of the elderly. women, and minorities in heart failure trials. Arch Intern Med 162 (2002) 1682-1688
32. McAlister F.A. Applying the results of systematic reviews at the bedside. In: Egger M., Davey Smith G., and Altman D.G. (Eds). Systematic reviews in health care: meta-analysis in context (2001), BMJ Books, London
33. Kalra L., Yu G., Perez I., Lakhani A., and Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stoke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 320 (2000) 1236-1239
34. Evans S.J.W. Statistics: analysis and presentation of safety data. In: Talbot J., and Waller P. (Eds). Stephen's detection of new adverse reactions. 5th edn. (2004), John Wiley & Sons, Chichester
35. Teo K.K., Yusuf S., and Furberg C.D. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA 270 (1993) 1589-1595
36. Beral V., Banks E., and Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360 (2002) 942-944
37. Califf R.M. Clinical trials bureaucracy: unintended consequences of well-intentioned policy. Clin Trials 3 (2006) 496-502
38. Eisenstein E.L., Collins R., Cracknell B.S., et al. Sensible approaches for reducing clinical trial costs. Clin Trials 5 (2008) 75-84
39. Rochon P.A., Gurwitz J.H., Sykora K., et al. Readers guide to critical appraisal of cohort studies, 1: role and design. BMJ 330 (2005) 895-897
40. Ioannidis J., Haidich A.-B., Pappa M., et al. Comparison of evidence of treatment effects in randomised and non-randomised studies. JAMA 286 (2001) 821-830
41. Doll R., and Peto R. Randomised controlled trials and retrospective controls. BMJ 280 (1980) 44
42. MacMahon S., and Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 357 (2001) 455-462
43. Glasziou P., Chalmers I., Rawlins M., and McCulloch P. When are randomised trials unnecessary? Picking signal from noise. BMJ 334 (2007) 349-351
44. Normand S.-L., Sykora K., Li P., Mamdani M., Rochon P.A., and Anderson G.M. Readers guide to critical appraisal of cohort studies, 3: analytical strategies to reduce confounding. BMJ 330 (2005) 1021-1023
45. Byar D.P., Schoenfield D.A., Green S.B., et al. Design considerations for AIDs trials. N Engl J Med 323 (1990) 1343-1348
46. Hill A.B. The environment and disease: association or causation?. Proc R Soc Med 58 (1965) 295-300
47. Stampfer M.J., and Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med 20 (1991) 47-63
48. Grady D., Rubin S.M., Pettiti D.B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 117 (1992) 1016-1037
49. Herrington D.M. Hormone replacement therapy and heart disease: replacing dogma with data. Circulation 107 (2003) 2-4
50. Petitti D.B., and Freedman D.A. How far can epidemiologists get with statistical adjustment. Am J Epidemiol 162 (2005) 415-418
51. Boston Collaborative Drug Surveillance Group. Regular aspirin intake and acute myocardial infarction. BMJ 1 (1974) 440-443
52. Smithells R.W., Nevin N.C., Seller M.J., et al. Further experience of neural tube supplementation for prevention of neural tube defects. Lancet 1 (1983) 1027-1039
53. Gilbert R., Salanti G., Harden M., and See S. Infant sleeping position and sudden infant death syndrome: systematic review of observational studies and historical review of recommendations from 1940 to 2002. Int J Epidemiol 34 (2005) 874-887
54. Rostom A., Dubé C., Lewin G., et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for the primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med 146 (2007) 376-389
55. Academy of Medical Sciences. Identifying the environmental causes of diseases: how should we decide what to believe and when to take action (2007), Academy of Medical Sciences, London
56. Davey Smith G., and Ebrahim S. Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 33 (2004) 30-42
57. Sørensen H.T., Christensen S., Mehnert F., et al. Use of biphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336 (2008) 784-785
58. Anderson H.R., Ayres J.G., Sturdy P.M., et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ 330 (2005) 117-124
59. Boston Collaborative Drug Surveillance Program. Reserpine and breast cancer. Lancet 2 (1974) 669-671
60. Armstrong B., Skegg D., White G., and Doll R. Rauwolfia derivatives and breast cancer in hypertensive women. Lancet 2 (1976) 8-12
61. Heinonen O.P., Shapiro S., Tuominen L., and Turunen M.I. Reserpine use in relation to breast cancer. Lancet 2 (1974) 675-677
62. Grossman E., Messerli F.H., and Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 22 (2001) 1343-1352
63. Horwitz R.I., and Feinstein A.R. Exclusion bias and the false relationship of reserpine and breast cancer. Arch Intern Med 145 (1985) 1873-1875
64. Canadian Task Force on the Periodic Health Examination. The periodic health examination. CMAJ 121 (1979) 1193-1254
65. Agency for Healthcare Research and Quality. Systems to rate the strength of scientific evidence (2002), US Department of Health and Human Services, Washington, DC
66. Schünemann H.J., Fretheim A., and Oxman A.D. Improving the use of research evidence in guideline development, 9: grading evidence and recommendations. Health Res Policy Syst 4 (2006) 21
67. Hill A.B. Heberden Oration 1965b: reflections on the controlled trial. Ann Rheum Dis 25 (1966) 107-113
68. Freemantle N., and Irs A. Observational evidence for determining drug safety. BMJ 338 (2008) 627-628
69. Weinstein M.C., O'Brien B., Hornberger J., et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPO Task Force on Good Research Practices-modeling studies. Value Health 6 (2003) 9-17
70. Wald N.J., and Morris J.K. Teleoanalysis: combining data from different types of study. BMJ 327 (2003) 616-618
71. King M., Nazareth I., Lampe F., et al. Impact of participant and physician intervention preferences on randomised trials. JAMA 293 (2005) 1089-1099